Abstract:Atenolol is a selective beta 1-adrenoceptor antagonist with a duration of activity of at least 24 hours. The scope of therapeutic use of the drug has been expanded and become better defined since it was first reviewed in the Journal in 1979. Atenolol is effective and generally well tolerated in patients with all grades of hypertension. Data from comparative studies show that when administered orally, atenolol reduces blood pressure to a similar extent, and in a similar proportion of patients, as usual therapeutic doses of other beta-adrenoceptor antagonists (such as acebutolol, celiprolol, betaxolol, indenolol, metoprolol, nadolol, pindolol, propranolol, tertatolol), angiotensin converting enzyme (ACE) inhibitors (e.g. captopril, enalapril and lisinopril), calcium antagonists (e.g. amlodipine, diltiazem, felodipine, isradipine, nitrendipine, nifedipine, verapamil), doxazosin, ketanserin and alpha-methyldopa. Atenolol effectively lowers blood pressure in elderly patients with hypertension and in women with hypertension associated with pregnancy, and improves objective and subjective indices in patients with stable angina pectoris. Oral atenolol is used for preventing recurrence of supraventricular arrhythmias once control is achieved by intravenous administration of atenolol. Early intervention with intravenous atenolol followed by oral maintenance therapy reduces infarct recurrence and cardiovascular mortality in patients with known or suspected myocardial infarction. There is also encouraging evidence of reduced mortality from cardiovascular disease during long term therapy with atenolol in patients with hypertension. Atenolol is well tolerated in most patients. Increases in plasma levels of both total triglycerides and very low density lipoprotein (VLDL) triglycerides have accompanied atenolol therapy although the clinical relevance, if any, of longer term metabolic effects has yet to be determined. Its low lipid solubility and limited brain penetration results in a lower incidence of central nervous system effects than that associated with propranolol. After many years of clinical usage atenolol is a well established treatment option in several areas of cardiovascular medicine such as mild to moderate hypertension and stable angina pectoris. Furthermore, it has also shown potential in the treatment of some cardiac arrhythmias and has been associated with reduced cardiovascular mortality in patients with hypertension and in patients with myocardial infarction.

A synthesis on the sub-lethal toxicity of atenolol, a beta-blocker, in teleost fish

Waterborne atenolol disrupts neurobehavioral and neurochemical responses in adult zebrafish

Toxicity Risks Associated With the Beta‐Blocker Metoprolol in Marine and Freshwater Organisms: A Review

Using a High-Throughput Zebrafish Embryo Screening Approach to Support Environmental Hazard Ranking for Cardiovascular Agents.

Toxic effects of four cardiovascular drugs on the development and epigenetics of zebrafish (Danio rerio)

-blockers in the environment: Distribution, transformation, and ecotoxicity

Cardiovascular drugs and lipid regulating agents in surface waters at global scale: Occurrence, ecotoxicity and risk assessment

Toxicity Prediction and Effect Characterization of 90 Pharmaceuticals and Illicit Drugs Measured in Plasma of Fish from a Major European River (sava, Croatia)

The toxic effects of chronic atrazine exposure on the intestinal microbiota, metabolism and transcriptome of Pelophylax nigromaculatus larvae

Environmental Occurrence and Predicted Pharmacological Risk to Freshwater Fish of over 200 Neuroactive Pharmaceuticals in Widespread Use

Assessment of the ecotoxicity of the pharmaceuticals bisoprolol, sotalol, and ranitidine using standard and behavioral endpoints

Toxic effects of acute and chronic atorvastatin exposure on antioxidant systems, autophagy processes, energy metabolism and life history in Daphnia magna

Medicine designed to combat diseases of affluence affects the early development of fish. How do plastic microparticles contribute?

(+) anatoxin-a elicits differential survival, photolocomotor behavior, and gene expression in two alternative vertebrate models

Fate of beta blockers in aquatic-sediment systems: sorption and biotransformation

From bacteria to fish: ecotoxicological insights into sulfamethoxazole and trimethoprim

The potential for adverse effects in fish exposed to antidepressants in the aquatic environment

Toxicity of selected pharmaceuticals and their mixtures to the aquatic indicators Daphnia magna and Aliivibrio fischeri

Environmental presence and toxicological outcomes of the herbicide pendimethalin in teleost fish

Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders

Metabolomic‐Based Comparison of Daphnia magna and Japanese Medaka Responses After Exposure to Acetaminophen, Diclofenac, and Ibuprofen